Efficacy of idebenone to preserve respiratory function above clinically meaningful thresholds for forced vital capacity (FVC) in patients with Duchenne muscular dystrophy

This post-hoc analysis evaluated whether idebenone reduced the risk of dropping below clinically meaningful FVC % predicted thresholds in 31 patients aged 10–18 years with Duchenne muscular dystrophy, as compared with 33 patients receiving placebo. FVC and FVC % predicted was assessed at screening, baseline and at Weeks 13, 26, 39, and 52 using a Vitalograph Pneumotrac spirometer.